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BACKGROUND: Since the launch of the National Cancer Survivorship Initiative, there has been a surge of interest surrounding the value
and organisation of long-term follow-up care after cancer treatment. We report the views of 309 adult cancer survivors (aged 18–45
years) on provision of follow-up and preferences for care.
METHODS: A total of 207 survivors completed questionnaires before and after routine consultant-led follow-up appointments and 102
were recruited by post. Measures of health status (including late effects, perceived vulnerability to late effects and quality of life),
reasons for attending follow-up (clinical and supportive), issues to be discussed at follow-up and preferences for different models of
care were assessed.
RESULTS: In all, 59% of the survivors reported experiencing one or more cancer-related health problems. Survivors rated clinical
reasons for attending follow-up more highly than supportive reasons (Po0.001), although nutritional advice and counselling were
considered useful (60 and 47%, respectively). Those still receiving scheduled follow-up appointments did not discuss the range of
issues intended with ‘late effects’ and ‘fertility’, which were particularly under-discussed. Hospital rather than GP follow-up was more
highly rated.
CONCLUSION: Survivors value the clinical reassurance currently provided by consultant-led care. However, supportive needs are not
systematically addressed. Multi-disciplinary services are recommended to meet supportive needs in addition to clinical care.
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Many younger adults aged 18–45 years diagnosed with cancer can
expect to live for decades after treatment but face particular
problems with regard to fertility and continuing in the work place.
Breast cancer is one of the most common malignancies diagnosed
in women under the age of 45 years, with a 5-year survival rate now
in excess of 80% (Walters et al, 2009). In this age range, testicular
cancer and Hodgkin’s lymphoma also represent a considerable
cancer burden, and again 5-year survival rates are very high at
B98 and 90%, respectively (Nur et al, 2008; Walters et al, 2009).
The good prognosis for this enlarging patient group raises
questions with regard to long-term follow-up and delivery of
services that are both clinically appropriate and meet individual
patient’s requirements.
Traditionally, the primary aim of follow-up has been to detect
acute problems related to treatment and cancer recurrence, but
increasing survival rates have led to a greater understanding of the
long-term physical and psychological effects that survivors may
experience years after treatment (Stein et al, 2008). Termed ‘late
effects’, these include infertility, osteoporosis, endocrine dysfunc-
tion, fatigue and depression (Kattlove and Winn, 2003; Stein et al,
2008). Consequently, follow-up services that identify and treat
long-term health implications of cancer have been recommended
(Aziz, 2007; Stein et al, 2008). To date, there has been little
consensus on the value and organisation of follow-up (Montgom-
ery et al, 2007). The importance of developing new and improved
post-treatment services has been highlighted by The Cancer
Reform Strategy (Department of Health, 2007), the subsequent
National Cancer Survivorship Initiative and by the NICE Improv-
ing Outcomes in Children and Young People with Cancer
(National Institute for Health and Clinical Excellence, 2005).
With increasing cancer survival rates, it is essential for long-
term care to adapt itself to meet demands. In a paediatric setting,
risk-based follow-up has been recommended, whereby patients are
stratified to services (primary care based, nurse led or consultant
led) depending on their treatment history and likelihood of further
health problems (Oeffinger et al, 2000; Wallace et al, 2001; Geenen
et al, 2007). A similar approach may also prove to be useful in an
adult setting, in which recommendations have been made for the
transfer of breast cancer survivors to general practice (National
Institute for Health and Clinical Excellence, 2002). Determining
patients’ views of care or preference for alternative models should
be an important consideration before changes to services are
implemented. The few studies to date, which have sought to
determine patients’ opinions, have done so by tumour group
(Moore et al, 2002; Papagrigoriadis and Heyman, 2003; Dancey
et al, 2005; Cox et al, 2006; Kew et al, 2007; Knowles et al, 2007),
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swith breast cancer patients evaluated the most (Grunfeld et al,
1996; Gulliford et al, 1997; Rojas et al, 2000; Collins et al, 2004; Jiwa
et al, 2006; Donnelly et al, 2007). There has not, however, been a
specific focus on how late effects are managed or on survivors’
experiences and expectations of follow-up services.
In this study, we first examine survivors’ views on their health
(current late effects, perceived vulnerability to late effects and
quality of life), and second, determine survivors’ reasons for
attending follow-up and preferences for alternative models of care.
Third, survivors attending follow-up appointments were asked
about their preferences for further supportive services and the
issues they planned to discuss during follow-up appointments.
MATERIALS AND METHODS
Eligibility criteria
This was a cohort study of younger adults treated for cancer with
curative intent at a regional cancer centre in Sheffield, UK, serving
a population of 1.8 million. In the absence of a clear definition of
younger adult cancer patients, we specified the age range of eligible
participants to be 18–45 years, as younger adults have historically
been the explicit focus of our previous research and clinical
interest. There is a paucity of evidence examining the efficacy of
long-term follow-up in the identification of late effects, particularly
in younger adults who are likely to have more complex needs in
terms of fertility, duration of survival, employment and family
issues. We chose to focus on the main tumours typically diagnosed
in younger adults (haematological cancers (lymphoma or acute
leukaemia), germ cell or breast cancer). Survivors were required to
be a minimum of 5 years from diagnosis without relapse (2 years
from diagnosis for the germ cell group). Terminally ill patients and
those not fluent in English or unable to provide written informed
consent were excluded.
Procedure
During the study period (from December 2006 to January 2008),
eligible survivors were identified from hospital databases and
clinic lists. Those receiving follow-up care during this period were
contacted by post and invited to participate 1 week before
appointments. Consultant-led care was the mode of follow-up
received by this group during the course of our study. Completed
questionnaires were collected at the clinic before follow-up
consultations. Patients attending the clinic were also asked to
complete a second questionnaire at home after their appointment.
Eligible survivors not currently receiving follow-up care at the
specialist centre were contacted by post and invited to participate.
Questionnaires completed at home were returned in freepost
envelopes.
Participants
In total, 467 eligible patients were identified (see Figure 1). A total
of 256 eligible survivors had follow-up appointments scheduled, of
whom 207 (80.9%) completed Time 1 questionnaires and 153 out
of 207 (73.9%) returned Time 2 questionnaires. In all, 211
survivors were eligible for postal recruitment only, of whom 102
returned questionnaires (48.3%). In total, 158 survivors declined to
participate (breast n¼37, haematology n¼39 and germ cell
n¼82). Overall, 309 survivors (response rate¼66.2%, breast
n¼75, haematology n¼131, germ cell n¼103) participated in
this study. The current age of participants (mean¼37.9 years) was
comparable with those who declined participation (mean¼36.9
years, P¼0.08, difference:  1.02, CI:  2.18 to 0.14).
Measures
Time 1
(1) Demographic information
(2) Reasons for attending follow-up care: Survivors rated the
importance of follow-up on two scales adapted from Absolom
et al (2006), measuring (a) clinical care (five items) and (b)
supportive care (four items, see Table 4). Items were rated
from 1 to 5, with higher scores indicating greater importance.
(3) Supportive services: Four supportive services identified
through a consultation exercise with both clinicians and
cancer survivors were listed (support groups, counselling,
Eligible patients identified
(n = 467)
Survivors attending follow-up
during study period
(n = 256/467, 54.8%)
Survivors eligible for postal
recruitment (discharged or without
follow-up appointment scheduled
during study period)
(n = 211/467, 45.2%)
T1 questionnaire
completed before
follow-up consultation
(n = 207/256, 80.9%)  
Declined
(n = 49/256,
19.1%)
T2 questionnaire
completed
(n = 153/207,
73.9%)  
Postal
questionnaires
returned
(n = 102/211,
48.3%)
Postal
questionnaires
not returned
(n = 109/211,
51.7%)
Total sample
(n = 309/467, 66.2%
response rate)
Figure 1 Participant recruitment.
Younger adult views of follow-up after cancer
K Absolom et al
562
British Journal of Cancer (2009) 101(4), 561–567 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
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employment/careers). Survivors indicated how helpful they
thought each would be on a 5-point scale, with 1 being ‘not at
all helpful’ to 5 being ‘very helpful’. Space was also provided
for respondents to document other services they thought were
helpful.
(4) Issues to be discussed during consultations (Absolom et al,
2006): Ten issues were listed, including current health,
medication, fertility, late-effects insurance and an ‘anything
else’ option. Survivors were asked whether they wanted to
discuss each issue during their next follow-up visit. Total
number of issues was computed (0–10).
(5) Current late effects and vulnerability: A list of 18 possible
cancer-related health problems was presented (e.g., infertility,
lung damage, fatigue, depression and developed from a
measure previously used by Absolom et al (2006)). Partici-
pants were asked to rate their perceived vulnerability to each
problem on a 5-point scale, from ‘very unlikely’ to ‘very likely’.
A further alternative response was also provided: ‘I already
have this problem’. This scale yields two scores, namely, total
number of late effects (0–18) and vulnerability (range 1–5), in
which higher scores indicate greater perceived vulnerability.
(6) Health-related quality of life (HRQOL): The SF-12v2 (Ware
et al, 2002) is a 12-item measure that can produce two
summary scores, namely Physical Component Summary (PCS)
and Mental Component Summary (MCS). The PCS and MCS
are scaled to have a mean score of 50 and a s.d. of 10, in line
with the reference population.
Time 2 After clinic appointments, survivors were asked to
complete the following measures:
(1) Issues discussed: The same 11 issues presented at Time 1 were
used, and survivors indicated those that they discussed with
clinic staff.
(2) Preferences for follow-up care: To determine the acceptability
of different models of follow-up care, survivors were presented
with four descriptions of care, namely postal/telephone follow-
up, GP led, nurse led and consultant led. Four statements were
presented with each description (‘I think this type of care would
suit me’; ‘If I had this type of care I would worry that any
problems with my health would not be found’; ‘I would be
happy with this type of care’; and ‘This type of care would
definitely meet my follow-up needs’). Survivors rated how far
they agreed or disagreed with each statement on a 5-point scale.
Overall sum scores were generated for each form of care (range
4–20), with higher scores denoting a more positive view.
Survivors without scheduled follow-up appointments completed
an abridged postal questionnaire consisting of the following
measures:
(1) demographic information;
(2) reasons for attending follow-up care;
(3) current late effects and vulnerability;
(4) HRQOL (SF-12 v2);
(5) preferences for follow-up care.
Medical information and disease severity
Information on diagnosis, time since completion of treatment and
treatment (chemotherapy, radiotherapy or surgery) was obtained
for each participant from medical records. Given the hetero-
geneous nature of the tumour groups, a disease severity scoring
system was developed by clinicians from the tumour-specific
teams to enable us to describe our population, allowing for
comparisons across the different cancers. Individuals were
assigned one of three scores: 1¼localised (i.e., localised and
indolent), 2¼intermediate (i.e., generalised indolent/localised
aggressive), 3¼disseminated (i.e., generalised and aggressive).
Cases were allocated by a member of the clinical team.
A proportion was rated a second coder, blind to the original
decision. Any ambiguous codes were referred to the relevant
consultant for a final decision.
Analysis
Analyses were conducted using SPSS version 11 (SPSS Inc.,
Chicago, IL, USA). Internal reliabilities of all scales were assessed
using Cronbach’s alpha. w
2, t-tests and analysis of variance
(ANOVA) (with post hoc Tukey’s tests) were used to compare
differences in demographic and clinical variables and question-
naire measures. Age was found to be associated with number of
reported late effects and vulnerability scores and was consequently
entered as a covariate in univariate analysis, in which the three
tumour groups were compared. Multiple regression analysis was
used to determine variables associated with the number of reported
late effects. The variables entered into the regression were age at
study, tumour group (entered as two dummy variables with breast
as the reference group) and treatment; surgery (yes/no), chemo-
therapy (yes/no) and radiotherapy (yes/no). To determine how the
sample’s HRQOL compared with population data, individual
survivor scores for PCS and MCS subscales were matched to the
appropriate age- and sex-matched normative SF-12v2 data. Scores
were then compared using paired sample t-tests. Pearson’s
correlations were used to identify associations between demo-
graphic variables, HRQOL scores, reasons for attending follow-up
and number of issues discussed during consultations. The
percentage of survivors reporting ‘very important’ for each reason
for attending follow-up was used to rank the importance of each
item. McNemar’s test for paired nominal data was used to compare
the percentage of survivors who intended to discuss each issue
during their consultation with those who did. A P-value of o0.05
represents a significant difference between the two proportions.
RESULTS
Results are first presented for the entire cohort (assessing current
health, reasons for follow-up and follow-up preferences) and
second for the sub-sample of survivors who attended scheduled
follow-up during the study period and completed items on issues
to discuss and supportive services.
Table 1 provides clinical information about the sample,
including disease severity scores. Overall, the demographic and
clinical characteristics of the sample are in line with those of
tumour group populations, with the breast sample being older
than the other groups. At the time of the study, the germ cell group
was fewer years from treatment than were the other samples. This
reflects an earlier routine discharge practice for germ cell survivors
than for breast and haematology cancer patients.
Current health: late effects, perceived vulnerability and
HRQOL
Of survivors, 59.2% (183 out of 309, CI: 54–65%) reported one or
more late effects as a consequence of their cancer (breast¼73.3%,
CI: 62–82%; haematology¼64.9%, CI: 56–73%; germ
cell¼41.7%, CI: 33–51%). The mean number of reported late
effects for the whole group was 1.6 (Table 2). Survivors with a
disease severity score of 3 reported more late effects than did those
with scores of 2 or 1 (means¼2.0, 1.8 and 1.3, respectively),
although differences were not significant (P40.05). After adjusting
for age, significantly fewer late effects (Table 2) were reported by
germ cell survivors (mean¼1.1) than by either breast (mean¼1.9)
or haematology groups (mean¼1.9). The top three most
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sfrequently reported late effects by each tumour group are listed in
Table 2.
The results of the multivariate regression for total number of
reported late effects are shown in Table 3. Older age at the time of
study and having received chemotherapy were both associated
with more reported late effects.
Vulnerability scores were o3 for all tumour groups (Table 2).
After adjusting for age, the germ cell group reported the lowest
vulnerability, which was significantly less than that of the
haematology group (Po0.05) but not of the breast group
(P¼0.30). Women reported higher vulnerability than did men
(means¼2.7 vs 2.5, Po0.05, difference:  0.18, CI:  0.34 to  0.03).
In general, survivors compared favourably with age- and sex-
matched normative data for SF-12 PCS and MCS. The only
exception was the breast group, who reported worse MCS than the
normative data (Po0.05). More reported late effects were
associated with worse PCS (r¼ 0.39, Po0.001) and MCS scores
(r¼ 0.25, Po0.001). Higher perceived vulnerability to late effects
was also associated with worse PCS (r¼ 0.27, Po0.001) and MCS
scores (r¼ 0.32, Po0.001).
Reasons for attending follow-up care
Clinical reasons for follow-up care were more highly rated than
were supportive reasons (means¼4.6 vs 3.6, difference: 1.03, CI:
0.95–1.11; Po0.001). The rank order of each of the reasons for
follow-up items is shown in Table 4. Checking for cancer
recurrence and obtaining reassurance were the most highly rated
Table 2 Late effects, vulnerability, health-related QOL (SF-12v2) scores and preference for follow-up
Breast
(N¼75)
Haematology
(N¼131)
Germ cell
(N¼103)
Total
(N¼309)
Late effects
a range 0–18 Total mean (CI) 1.9 (1.5–2.4) 1.9 (1.6–2.2) 1.1 (0.7–1.5) 1.6 (1.4–1.9)
Most common late effects % (n/N) First Weight gain Infertility Testicular/ ovarian damage
32.0 (24/75) 28.2 (37/131) 26.2 (27/103)
Second Lymphoedema Thyroid damage Infertility
30.7 (23/75) 21.4 (28/131) 12.6 (13/103)
Third Mood swings Chronic fatigue Hearing loss
29.3 (22/75) 17.6 (23/131) 10.7 (11/103)
Vulnerability to late effects
b range 1–5 Mean (CI) 2.6 (2.4–2.7) 2.7 (2.6–2.8) 2.4 (2.3–2.5) 2.6 (2.5–2.6)
Health-related QOL
c Physical component
summary (CI)
52.8 (50.9–54.7) 52.1 (50.6–53.7) 53.7 (52.0–55.4) 52.8 (51.8–53.8)
Mental component
summary (CI)
45.3 (42.8–47.8) 48.7 (47.1–50.3) 51.0 (49.3–52.7) 48.6 (47.5–49.7)
Breast
(N¼71)
Haematology
(N¼102)
Germ cell
(N¼82)
Total
(N¼255)
Follow-up preferences mean (CI) Consultant led 16.4 (15.8–17.0) 17.2 (16.7–17.7) 17.0 (16.4–17.6) 16.9 (16.6–17.2)
Range 4–20 Nurse led 12.9 (12.0–13.9) 13.7 (13.0–14.5) 13.4 (12.6–14.2) 13.4 (12.9–13.9)
Telephone/
questionnaire
10.0 (8.9–11.0) 10.2 (9.3–11.1) 11.3 (10.4–12.2) 10.5 (10.0–11.0)
GP based 9.6 (8.5–10.6) 9.4 (8.5–10.2) 9.8 (8.9–10.8) 9.6 (9.0–10.1)
CI¼confidence interval; GP¼general practitioner; MCS¼Mental Component Summary; PCS¼Physical Component Summary; QOL¼quality of life.
aMeans adjusted for age,
germ cell obreast (Po0.05) and haematology (P¼0.01)
bMeans adjusted for age, germ cell ohaematology (Po0.05).
cThe PCS and MCS are scaled to have a mean score of
50 and s.d. 10 in line with the reference population.
Table 1 Study sample
Breast (N¼75) Haematology (N¼131) Germ cell (N¼103) Total (N¼309)
Demographics
Age (s.d.) 41.2 (3.1) 37.9 (5.6) 35.7 (6.6) 37.9 (5.8)
Years since end of treatment (s.d.) 6.2 (2.4) 11.8 (5.1) 4.7 (3.0) 8.1 (5.1)
Male % (n/N) 0 (0/75) 50.4 (66/131) 92.2 (95/103) 52.1 (161/309)
Treatment % (n/N)
Surgery 100.0 (75/75) 41.2 (54/131) 98.1 (101/103) 74.4 (230/309)
Chemotherapy 90.7 (68/75) 88.5 (116/131) 50.5 (52/103) 76.4 (236/309)
Radiotherapy 81.3 (61/75) 72.5 (95/131) 34.0 (35/103) 61.8 (191/309)
Disease severity % (n/N)
1 (localised disease) 60.0 (45/75) 18.3 (24/131) 64.1 (66/103) 43.7 (135/309)
2 (intermediate disease) 40.0 (30/75) 55.7 (73/131) 26.2 (27/103) 42.1 (130/309)
3 (disseminated disease) 0 (0/75) 26.0) (34/131) 9.7 (10/103) 14.2 (44/309)
Table 3 Multivariate regression analysis showing variables associated
with total number of reported late effects
Unstandardised B P-value
95% confidence
intervals
Age at study 0.055 0.008 0.02–0.10
Breast vs haematology 0.145 0.681  0.55–0.84
Breast vs germ cell  0.504 0.193  1.26–0.26
Surgery 0.240 0.478  0.43–0.91
Radiotherapy  0.012 0.964  0.55–0.52
Chemotherapy 0.667 0.037 0.04–1.29
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sreasons and getting advice with regard to everyday matters was the
least. Women scored significantly higher than did men for both
scales (clinical means¼4.7 vs 4.6, difference:  0.10, CI:  0.19 to
 0.01; Po0.05; supportive means¼3.7 vs 3.5, difference:  0.22,
CI:  0.41 to  0.02; Po0.05). There were no significant differences
between the three disease severity groups (clinical means: level
1¼4.6, level 2¼4.6, level 3¼4.6, P¼0.95; supportive means: level
1¼3.5, level 2¼3.6, level 3¼3.5, P¼0.43). The scores for
participants with follow-up appointments during the study period
were not significantly different than for those without (clinical
means 4.6 vs 4.5, difference: 0.09, CI:  0.01–0.19; supportive
means¼3.6 vs 3.5, difference 0.03, CI:  0.18–0.24). The breast
sample rated supportive reasons significantly more highly than did
the germ cell group (3.8 vs 3.5, Po0.05); there were no
other differences between the tumour groups. Higher suppor-
tive scores were associated with higher vulnerability (r¼0.24,
Po0.001).
Preferences for alternative models of follow-up
Regardless of tumour group or disease severity, consultant-led care
was preferred over nurse-led, telephone follow-up and GP-based
care (see Table 2). There were also no associations between follow-
up preferences and disease severity, number of reported late
effects, vulnerability or HRQOL (data not shown).
Supportive services and issues discussed during
consultations
Nutritional advice from a dietician was the most highly rated of the
support services, with 59.9% (124 out of 207, CI: 53–66%) of
survivors reporting that they would find this useful. The next most
popular service was counselling (46.9%, 97 out of 207; CI: 40–
54%), followed by support groups (45.9%, 95 out of 207; CI: 39–
53%) and employment/careers advice (28.5%, 59 out of 207, CI:
23–35%). Additional services of value that survivors identified
included advice on exercise, holistic therapies, physiotherapy, as
well as medical tests and information (including advice on fertility,
late effects and reducing the risk of cancer recurrence).
The total number of issues that the survivors intended to discuss
at Time 1 and Time 2 did not differ across tumour groups (Time 1
mean scores: breast¼3.5, haematology¼3.4, germ cell¼3.6,
P¼0.80; Time 2 mean scores: breast¼2.3, haematology¼2.6,
germ cell¼2.3, P¼0.48). Survivors attending follow-up appoint-
ments who returned Time 2 questionnaires (N¼153) reported
discussing significantly fewer issues during consultation than they
had intended (means¼3.4 vs 2.4, difference: 1.01, CI: 0.64–1.4;
Po0.001). Table 5 shows the percentage of survivors intending to
discuss each issue before their consultation compared with what
they reported discussing afterwards. There were clear discrepan-
cies between Time 1 and Time 2 percentages for late effects, health
behaviours, fertility and insurance.
The number of issues that the survivors intended discussing
was associated with higher ratings for supportive (r¼0.48,
Po0.001) and clinical reasons for follow-up (r¼0.26, Po0.001),
as well as with higher feelings of vulnerability (r¼0.23, Po0.01).
In comparison, the number of issues they reported actually
discussing during consultations was associated with more
reported late effects (r¼0.21, Po0.05) and worse PCS
(r¼ 0.20, Po0.05).
DISCUSSION
Although these young adult cancer survivors reported comparable
HRQOL with age- and sex-matched normative data, B60%
experienced cancer-related problems. On an average, the sample
was 8 years from treatment, but expectations with regard to follow-
up were still focussed on checking for cancer recurrence and on
obtaining reassurance. In concordance with this finding, hospital-
based follow-up was more highly rated than was the prospect of
transfer to general practice, although many survivors were in
favour of access to supportive services, including advice from a
dietician and counselling.
The breast cancer survivors were the only group to report
significantly worse HRQOL than normative data. This was for
mental rather than for physical health, and supports findings from
previous research suggesting younger breast cancer survivors fare
worse psychologically than do their older counterparts (Ganz et al,
2003). Indeed, a considerable proportion of breast cancer survivors
in this study reported problems with mood, as well as with weight
gain and lymphoedema. Commonly reported problems in the rest
of the sample included infertility, chronic fatigue and gonadal
dysfunction. Although the germ cell group reported fewer late
effects than did both the breast and haematology survivors,
regression analysis indicated that older age at the time of study and
having received chemotherapy were the two variables significantly
associated with more reported late effects. These findings reflect the
wide range of health issues effecting survivors and the complexity of
providing follow-up services, which meet both the physical and
psychological needs of individual patients in the long term.
Across all tumour groups, checking for cancer recurrence and
getting reassurance were rated as the most important reasons for
attending follow-up care. Supportive issues were consistently
ranked lower, a finding that is in line with clinicians’ views of the
purpose of continued care (Greenfield et al, 2009). After the end of
treatment, recurrence is a major fear for many patients; hence, this
finding is not surprising. However, attending follow-up may
provide a false reassurance, as evidence suggests recurrences can
often be detected between scheduled follow-up appointments
Table 4 Rank order of survivors’ ratings of reasons for attending follow-
up
Ranks Item
% Survivors
reporting very
important
Scale
(C¼Clinical,
S¼Supportive)
1 Check for cancer recurrence 90.3 (279/309) C
2 Get reassurance about health 74.1 (229/309) C
3 Get the best medical care 68.3 (221/309) C
4 Help staff learn more about late
effects of cancer
50.2 (155/309) C
5 Get information about late effects 42.1 (130/309) C
6 Talk to staff who understand what
I have been through
23.6 (73/309) S
Get advice about how to keep
healthy
23.0 (71/309) S
7 Receive psychological support 16.8 (52/309) S
8 Get advice about everyday things,
such as insurance
10.7 (33/309) S
Table 5 Percentage of survivors (N¼153) intending to discuss each
issue before follow-up consultation and those they report discussing
T1 Intend to
discuss % (n)
T2 Report
discussing % (n) P-value
Current health 86.3 (132) 86.9 (133) 0.728
Late effects 77.8 (119) 35.9 (55) o0.001
Health behaviours 47.7 (73) 32.7 (50) 0.007
Fertility 32.0 (49) 15.0 (23) o0.001
Medication 31.4 (48) 30.1 (46) 1.000
Insurance 23.5 (36) 2.0 (3) o0.001
Work/education 15.7 (24) 13.1 (20) 0.597
Sexual problems 12.4 (19) 5.2 (8) 0.019
Contraception 11.8 (18) 3.9 (6) 0.001
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s(Grunfeld et al, 1996). In addition, our patient sample was typically
many years from the end of treatment (mean 8.1 years) and the
risk of recurrence is therefore low.
Regardless of tumour group, number of reported late effects or
disease severity, preferences for follow-up showed a marked bias
towards hospital-based services over telephone or GP-based care.
This is in contrast to recent recommendations, including those for
breast cancer patients, proposing the transfer of survivors to
primary care (National Institute for Health and Clinical Excellence,
2002). Given the fact that our sample only had experience of
consultant-led care and that the other proposed models were
hypothetical, it is understandable that many would show allegiance
to specialist services in which they are both familiar and have
confidence. The introduction of alternative models of follow-up,
such as nurse-led or GP-based services, will have to contend with
the ethos (created by both patients and staff) that consultant care
is the optimal option, despite the fact that former models may be
better equipped to meet supportive care needs. In a systematic
review of breast cancer follow-up, Montgomery et al (2007) report
that patients followed up by breast cancer nurses report higher
satisfaction than do those receiving care from doctors, and that
QOL is similar between the two groups. The recent draft NICE
breast cancer guidelines (National Institute for Health and Clinical
Excellence, 2009) call for greater patient choice in defining follow-
up services. However, for an informed choice, patients may require
a better understanding of the purpose of follow-up and the roles
that different health-care professionals can have in assisting with
clinical and supportive problems. Importantly, the evidence
suggesting that cancer recurrence is typically detected by patients
between follow-up appointments needs to be relayed to patients
and supported with advice on the recognition of symptoms that
require clinical assessment and possible investigation.
In spite of the emphasis placed on cancer recurrence, survivors
expressed a wish to discuss a range of issues and concerns during
follow-up consultations. Besides general matters with regard to
current health and medication, many wanted to discuss late effects
and fertility, and a considerable percentage hoped for advice with
regard to health behaviours. Despite this, most survivors reported
the discussion of significantly fewer issues than they had indicated
before consultations. Most strikingly, 36% of survivors reported
discussing late effects, although 78% had hoped to. The total
number of issues that the survivors intended to discuss was
associated with personal views of follow-up and perceived
vulnerability to late effects. In contrast, the number of issues they
reported discussing was associated with more medical variables
(number of late effects and physical health). This suggests that a
medical agenda and time limitations may be the most influential in
the content of follow-up consultations. Further qualitative research
may be necessary to examine survivors’ opinions on what governs
the content of consultations and why certain topics are not
discussed. Patients may be reluctant to raise the discussion of
emotional and supportive issues in consultations, fearing they are
wasting the doctor’s time. In recognition of this, a recent study
describes the benefits of asking head and neck cancer patients to
complete a ‘concerns inventory’, the findings of which are
informed to the consultants (Rogers et al, 2009). This approach
may be one way of matching the content of consultations to patient
preferences more accurately.
Our results indicate that health behaviours were not frequently
discussed during consultations, despite the patient’s desire to do
so. Thus, health professionals are missing an opportunity to
promote healthy living. Although there is a growing body of
literature highlighting the role clinicians should undertake in
counselling survivors on the adoption of healthy lifestyles (Bellizzi
et al, 2005; Demark-Wahnefried et al, 2005; Sabatino et al, 2007),
there is no definitive guidance in this area. As with many follow-up
services, the survivors in our study were mainly seen in clinics
alongside patients on active treatment. Under the typical time
pressures many clinicians face, greater attention is understandably
focussed on acutely ill patients. Many doctors may not see it as
their role to deliver general lifestyle advice to survivors. However,
a significant proportion of the current sample wanted to discuss
health behaviours and B60% said nutritional advice would be a
useful addition to current follow-up care. Perhaps a different
forum is required to provide the supportive services survivors
seem to want, alongside clinical reassurance with regard to their
health. Specialist nurses and GPs may be more suitably positioned
and experienced to either provide this type of care or effectively
sign-post to appropriate services and agencies (Greenfield et al,
2009). Future follow-up care needs to address how best to integrate
these multi-disciplinary services.
This study involved a sizeable sample of younger adult cancer
survivors with particular age-associated needs from representative
tumour groups. It is the first to specifically explore views of follow-up
services in this population. Our study had a number of limitations.
First, survivors were recruited from a single cancer centre and may
not be representative of patients from other centres. Second, we have
relied on survivors’ self-reports of current late effects and topics
discussed during consultations without medical data or doctor’s
reports to verify results. Third, the issues of follow-up that we
surveyed were generic rather than tumour-specific issues. For
example, there are recognised issues pertinent to each tumour group,
such as monitoring endocrine therapy for breast cancer survivors,
that require a more detailed tumour-specific approach but were not
addressed in this survey. Fourth, we acknowledge the fact that the
generalisability of our findings is li m i t e dt ot h ea g er a n g ew es t u d i e d ,
which represents only 10% of the entire cancer population (Horner
et al, 2008). However, the excellent survival rates for many cancers
affecting younger adults, coupled with their complex requirements in
terms of fertility, employment and family issues, present unique
challenges for the development of long-term follow-up care. Fifth, we
recruited survivors several years from the end of treatment, whose
needs and perceptions may differ from those who have more recently
completed treatment. Finally, we had limited clinical information on
survivors who declined to participate in this study and hence are
unable to establish how representative our non-responders were
compared with the study participants. Although challenging, future
research should aim at determining the views and needs of survivors
who routinely miss appointments and those who become lost to
follow-up, as they may be a particularly vulnerable group.
In concordance with users involved with the think-tank exercise
to launch the National Cancer Survivorship Initiative ‘Living with
and beyond cancer’ (March 2008), our results highlight the wide
range of follow-up needs occurring after cancer. Future research
may take into account the possible benefits of alternative or
complementary follow-up models. Consideration should be given
to both the economic impact of different models, as well the
training needs of health-care professionals delivering care.
Although the survivors involved in this study were satisfied with
consultant-led follow-up with its clinical focus, we recommend
that future services take a multi-disciplinary approach to
encompass both clinical and supportive needs across primary,
secondary and tertiary services.
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